Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial
Moshe Mittelman(Tel Aviv University), Katharina Modelska(FibroGen (United States)), Anıl Tombak(Mersin Üniversitesi), Krzysztof Mądry(Medical University of Warsaw), Rosemary Harrup(University of Tasmania), Tyson Lee(FibroGen (United States)), Inho Kim(Seoul National University), David H. Henry(Pennsylvania Hospital), John A. Glaspy(University of California, Los Angeles), Barbara Grabowska(Wroclaw Medical University)
Cited by 17
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
|The Lancet Oncology|2020|401
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
|Blood|2019|369
Cancer Detection with Whole-Body PET Using 2-[18F]Fluoro-2-Deoxy-D-Glucose
|Journal of Computer Assisted Tomography|1993|255